Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 19 Source: CRO
- €212.4 million turnover
-
€188.9 million
profit - 165 employees
-
31st Dec 18 Source: CRO
- €143.5 million turnover
-
€121.8 million
profit - 141 employees
- 7 more years available »
Ranking
By Turnover
(€212.4 million)- 323rd in Top Companies
- 40th in Health
- 38th in Pharma
- 52nd in Manufacturing
By Employees
(165)- 657th in Top Companies
- 80th in Health
- 60th in Pharma
- 97th in Manufacturing
- 165
- €212.4 million
Employees
- James Byrne General Manager
Latest News
- 7:01am Bank of Ireland paves way for negative rates on accounts with over €1m
- 6:56am Air Corps bid for search and rescue services would result in job losses, union warns
- 6:56am FBD, ICG and Uniphar under fire over executive pay
- May 07 US jobs growth slows despite reopenings and vaccinations
- May 07 Regulator expects FBD to pay ‘all reasonable costs’ of publicans, court told